623144-30-9

Downstream Products

• 916887-25-7 methyl (2S)-3-[2-(2,6-dichlorophenyl)-6-quinolyl]-2-[(3,5-dichloropyridine-4-carbonyl)amino]propanoate 
• 1072115-55-9 (S)-2-(2-bromo-3-oxo-7-oxa-spiro[3.5]non-1-en-1-ylamino)-3-[2-(2,6-dichloro-phenyl)-quinolin-6-yl]-propionic acid 
• 1072115-59-3 methyl (2S)-3-(2-(2,6-dichlorophenyl)quinolin-6-yl)-2-((2-bromo-3-oxo-7-oxa-spiro(3.5)non-1-en-1-yl)amino)propanoate 
• 1072115-57-1 (S)-3-[2-(2,6-dichloro-phenyl)-quinolin-6-yl]-2-(2-diethylamino-3,4-dioxo-cyclobut-1-enylamino)-propionic acid 
• 1072115-58-2 methyl (2S)-3-(2-(2,6-dichlorophenyl)quinolin-6-yl)-2-((3-oxo-7-oxa-spiro(3.5)non-1-en-1-yl)amino)propanoate 

Relevant academic research and scientific papers

2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS

The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals for the treatment of VLA-4 dependent inflammatory diseases such as for example asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis. Formula (I): wherein X is N or CH.